USFDA completes inspection at Cipla’s API manufacturing facility in Bengaluru

20 Jul 2019 Evaluate

US Food and Drug Administration (USFDA) has completed a routine cGMP inspection at Cipla’s API manufacturing facility in Virgonangar, Bengaluru. The inspection ended with 7 observations, none of which were repeat or related to data integrity. The inspection had conducted from June 15, 2019 to June 19, 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Cipla Share Price

1488.50 -41.85 (-2.73%)
07-Jan-2026 10:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1779.50
Dr. Reddys Lab 1258.50
Cipla 1488.50
Zydus Lifesciences 934.20
Lupin 2208.05
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×